Found 4 clinical trials
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1
- 0 views
- 10 Jan, 2025
- 1 location
Patient-centered, Optimal Integration of Survivorship and Palliative Care
The goal of this study is to develop and test the feasibility of a supportivecare model (POISE) for patients with metastatic Non-small Cell Lung Cancer(NSCLC). The main questions areis POISE feasible to deliver and acceptable to patientswhat is the effect of POISE on the distress patients feel related to their …
- 0 views
- 10 Jan, 2025
- 1 location
Personalized DC Vaccines in Non Small Cell Lung Cancer
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.
- 0 views
- 10 Jan, 2025
- 1 location
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, increased activation of the erythroblastic leukemia viral oncogene homologue (ERBB) or …
- 0 views
- 10 Jan, 2025
- 4 locations